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DObjective: Our study compares late mortality and valve-related morbidities between nonelderly patients (aged
<65 years) undergoing stented bioprosthetic or mechanical valve replacement in the aortic position.
Methods: We identified 1701 consecutive patients aged<65 years who underwent aortic valve replacement
between 1992 and 2011. A stented bioprosthetic valve was used in 769 patients (45%) and a mechanical valve
was used in 932 patients (55%). A stepwise logistic regression propensity score identified a subset of 361 evenly
matched patient-pairs. Late outcomes of death, reoperation, major bleeding, and stroke were assessed.
Results: Follow-up was 99% complete. The mean age in the matched cohort was 53.9 years (bioprosthetic
valve) and 53.2 years (mechanical valve) (P ¼ .30). Fifteen additional measurable variables were statistically
similar for the matched cohort. Thirty-day mortality was 1.9% (bioprosthetic valve) and 1.4% (mechanical
valve) (P ¼ .77). Survival at 5, 10, 15, and 18 years was 89%, 78%, 65%, and 60% for patients with bio-
prosthetic valves versus 88%, 79%, 75%, and 51% for patients with mechanical valves (P¼ .75). At 18 years,
freedom from reoperation was 95% for patients with mechanical valves and 55% for patients with bioprosthetic
valves (P ¼ .002), whereas freedom from a major bleeding event favored patients with bioprosthetic valves
(98%) versus mechanical valves (78%; P ¼ .002). There was no difference in stroke between the 2 matched
groups.
Conclusions: In patients aged<65 years, despite an increase in the rate of reoperation with stented bioprosthetic
valves and an increase in major bleeding events with mechanical valves, there is no significant difference in mor-
tality at late follow-up. (J Thorac Cardiovasc Surg 2014;148:1931-9)The emphasis to place on patient age with regard to valve
choice in aortic stenosis remains a perplexing dilemma in
select situations. The recent guidelines for aortic valve
replacement have removed age as an absolute determinant
in the decision-making process. Still, whether implicitly
stated or not, when deciding to implant a mechanical or bio-
prosthetic heart valve into a patient, age will always be a
consideration. The quandary betweenmechanical prostheses
and bioprostheses endures—superior prosthesis durability
and low likelihood of future reoperations with mechanical
implants at the expense of lifelong anticoagulation and the
associated increase in bleeding attributed towarfarin therapy.
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The Journal of Thoracic and CarPrior renditions of valve guidelines recommended that pa-
tients younger than age 65 years undergo implantation of a
mechanical prosthesis (barring contraindications to anticoa-
gulation therapy) whereas patients older than age 65 years
receive a bioprosthesis.1 The threshold of 65 years was
considered the inflection point where the risk of reoperation
secondary to structural valve deterioration (SVD) was low
enough that the advantage of a bioprosthesis (ie, removal of
warfarin therapy) outweighed the long-term durability
inherent to a mechanical prosthesis. Improvements in surgi-
cal outcomes for reoperations,2,3 perceived improvements
in the durability of newer-generation bioprostheses,4,5 and
the currently untested yet highly anticipated future use of
percutaneous valve-in-valve technology to treat SVD6 have
contributed to a steady trend toward implanting bioprostheses
into younger patients instead of mechanical prostheses.7,8
Despite this trend, there are contemporary single-
institution observational studies that suggest a mortality
benefit of mechanical prostheses over bioprosthetic pros-
theses in nonelderly patients.9-11 These studies suggest
caution when implanting bioprostheses into patients aged
younger than 65 years. In contrast, the only contemporary
randomized clinical trial to assess the issue revealed no
difference in survival out to 13 years.12 Considering thediovascular Surgery c Volume 148, Number 5 1931
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EMR ¼ electronic medical record
SVD ¼ structural valve deterioration
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Dpaucity of data and conflicting conclusions in the contem-
porary literature, we set out to compare late mortality and
valve-related morbidity between nonelderly patients under-
going implantation of a stented bioprosthetic or mechanical
valve in the aortic position at the Brigham and Women’s
Hospital. The purpose of our study was to delineate differ-
ences in outcomes at late follow-up and to see if the current
trend toward implanting bioprosthetic valves into younger
patient populations is justifiable.PATIENTS AND METHODS
With approval from an institutional review board, a review of the elec-
tronic medical record (EMR) was conducted to identify all patients aged
younger than 65 years undergoing an isolated aortic valve replacement
(AVR) with a bileaflet mechanical or stented bioprosthesis from January
1992. An isolated AVR was defined as an AVRwithout additional concom-
itant valvular, coronary, or ventricular procedures at the time of the indexed
operation. Concomitant aortic root and/or ascending aortic repair proce-
dures were included in the isolated AVR cohort, as were patients having
had cardiac surgery before the indexed operation. Exclusion criteria were
AVR using a pulmonary autograft, homograft, or stentless bioprostheses.
Of 6794 patients who underwent an AVR within the specified time frame,
1701 patients met the inclusion criteria. The primary outcome was late
survival. Secondary outcomes included stroke, major bleeding, and reoper-
ations at late follow-up.
The study cohort underwent a propensity-matched analysis to create
evenly matched patient-pairs with respect to measurable covariates, with
type of prosthesis implanted (ie, bileaflet mechanical or a second-
generation stented bioprosthetic prosthesis) at the time of the indexed oper-
ation being the only discernible difference. The remaining unmatched
patients were placed into a separate database and their outcomes were
also assessed. The investigators were blinded to any outcomes during the
matching process (Figure 1).
Unless warfarin therapy was indicated for other reasons (eg, atrial fibril-
lation or pulmonary embolism), patients receiving a bioprosthetic valve
were managed solely with antiplatelet therapy (ie, daily aspirin), whereas
patients receiving a mechanical valve received both antiplatelet and antico-
agulation therapy in combination (ie, daily aspirin and warfarin). Goals for
warfarin therapy were to maintain an international normalizing ratio be-
tween 2.0 and 3.0. The decision to implant a bioprosthetic or mechanical
valve was at the discretion of the primary surgeon and the patient at the
time of implantation.
Data Collection
Patient characteristics, medications, laboratory values, and in-hospital
outcomes of the index surgery were collected at the time of presentation
and extracted from the hospital’s EMR. Data on long-term outcomes
were collected by questionnaires, records requested from referring physi-
cians, and extraction from the EMR at follow-up visits. Mortality data,
including date and cause of death, were collected from the following sour-
ces: the Social Security Death Index, EMR, and the state Department of
Public Health and Registry of Vital Statistics. Nineteen patients with an in-
ternational residence were lost to follow-up.1932 The Journal of Thoracic and Cardiovascular SurTo acquire up-to-date data for the secondary outcomes of stroke, major
bleeding, and reoperations, questionnaires were mailed to all eligible study
patients residing in the United States and presumed alive as of October
2011 (N ¼ 1391). Questionnaires were mailed in serial succession begin-
ning in November 2011. Two additional mailings were sent in January
2012 and March 2012 for nonresponders. Patient-reported responses
were cross-referenced and corroboratedwith themost current EMR records
on file. For those patients where a questionnaire was unattainable, the time
point used for secondary outcomes was the last recorded visit on file in the
EMR. A responder bias analysis was performed to assess for potential
differences between patients who responded to the survey and those who
elected not to participate.
Patient demographics and hospital outcomes were coded and defined
according to the Society for Thoracic Surgeons Adult Cardiac Surgery data-
base specifications, version 2.52. In addition to late mortality and valve-
related morbidities, short-term outcomes were also assessed. Short-term
outcomes of interest were 30-day mortality, re-exploration for bleeding,
postoperative stroke, in-hospital cardiac arrest, complete heart block, time
on the ventilator, intensive care unit length of stay, and hospital length of
stay. Sudden, unexplained death was considered a cardiac-related mortality.
Propensity-Matched Cohort
We conducted a matched group analysis using propensity-matched
cases (stented bioprostheses) and controls (mechanical valves). Propensity
to receive bioprosthetic valves was evaluated using logistic regression an-
alyses done in 2 steps. Variables to be evaluated as predictors were selected
based on literature review, known confounding covariates for the outcomes
of interest, differences between the 2 patient groups (Table 1), and clinical
judgment. These variables were then classified as patient-dependent or
treatment-dependent and separate forward-stepwise regression analyses
were conducted for each variable set, including examinations for interac-
tion effects. Any variable with a P  .15 was entered into the final model,
which was an enter-method logistic regression. The final model consisted
of 11 variables: age, year of surgery, cardiopulmonary bypass time, etiol-
ogy of disease (ie, calcific, endocarditis, congenital, rheumatic, primary
aorta, or other), body mass index, reoperation, gender, hypertension,
congestive heart failure, operative status (elective, urgent, or emergent),
and ejection fraction. An interaction variable between the surgeon and
the year of surgery was also included to control for differences in patient
mix and clinical practice over time. The resulting adjusted predicted prob-
ability score for each patient was then used to select matched pairs based on
probability scores<.01 (a priori algorithm).
Statistical Analysis
Normally distributed continuous variables are presented as mean 
standard deviation. Non-normally distributed continuous variables are pre-
sented as median with interquartile range. Analyses of continuous variables
were done using the Student t test with Levine’s homogeneity of variance or
Mann-Whitney U test, as appropriate. Dichotomous variables were evalu-
ated using the Fisher exact test and are presented as a numerical value as
well as a percentage. Outcomes of interest were analyzed by Kaplan-
Meier analysis. Failure time date was compared using the log-rank test.
Life-table estimations of 5-year, 10-year, 15-year, and 18-year survival
curves are presented as cumulative percent standard error. Statistical an-
alyses were done using SPSS (version 13.0; IBM-SPSS Inc, Armonk, NY).RESULTS
Our study included1701patients (769 stented bioprosthetic
cases, 932mechanical cases; 14,848 patient-years of data;me-
dian follow-up 8-years). Baseline characteristics for the com-
plete cohort are presented in Table 1. Patients receiving a
bioprosthesis were older and had more hypertension andgery c November 2014
FIGURE 1. Flow chart for study design. AVR, Aortic valve replacement.
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Dhypercholesterolemia. Patients receiving a mechanical pros-
thesis had more strokes, endocarditis, prior cardiac surgery,
and a lower ejection fraction. To best replicate a clinical trial,TABLE 1. Baseline characteristics for the entire cohort
Type of valve implanted
P valueBioprosthetic Mechanical
Cases 769 932
Patient characteristic
Age (y) 55.8  7.9 51.1  9.7 .001
Female 28.2 (217) 28.6 (267) .871
Body mass index 28.6  5.8 28.8  6.8 .653
Hypertension 51.8 (398) 41.1 (383) .001
Hypercholesterolemia 52.4 (403) 42.0 (391) .001
Renal failure 3.6 (28) 3.2 (30) .688
Preoperative creatinine 1.1  0.9 1.1  0.8 .767
Previous stroke 2.7 (21) 5.0 (46) .024
Congestive heart failure 28.6 (220) 31.9 (297) .153
Endocarditis 5.3 (41) 8.4 (78) .017
New York Heart Association
functional class III-IV
31.3 (241) 32.5 (303) .638
Ejection fraction (%) 60 (55-65) 60 (50-63) .001
Operative characteristics
Previous cardiac surgery 6.9 (53) 20.5 (191) .001
Previous coronary bypass
graft
1.8 (14) 4.6 (43) .002
Previous valve 4.3 (33) 15.1 (141) .001
Cardiopulmonary bypass
time (min)
111 (85-154) 128 (97-180) .001
Ischemic time (min) 80 (61-114) 90 (69-125) .001
Concomitant aortic surgery 21.6 (166) 32.9 (307) .001
Data are presented as mean  standard deviation, % (n), or median (interquartile
range).
The Journal of Thoracic and Carweeffectivelymatched722patients (361 stented bioprosthetic
cases and 361mechanical controls; 5413 patient-years of data;
median follow-up 6.5 years; 42% of total cohort) using pro-
pensity scores. The predictive model from which matched-
pairs were derived was robust, with an area under the receiver
operator characteristic curve of 0.81. Baseline characteristics
for both the matched and unmatched cohorts are presented
in Table 2. There were no significant differences for any of
the measured covariates of interest in the matched cohort.
The distributions for the valves implanted are listed in Table
3. For the primary outcome of late survival follow-up was
99% complete (Table 4).
Secondary outcomes data was acquired on all patients as
noted above. Questionnaire response rate was 74% (1028
out of 1391). A responder bias analysis was performed to
compare patient survey responders to nonresponders.13
Other than responders having a trend toward older age at
the time of surgery (53  9 years vs 52  9 years for non-
responders;P¼ .098), no other discernible differences were
noted. Gender mix; preoperative medical history; and labo-
ratory data, incidence of stroke, complete heart block, car-
diac arrest, and reoperations for bleeding during the
postoperative period were similar between the 2 groups
(all variables P>.25, data not shown).Short-Term Outcomes
Mortality and morbidity were low for the duration of the
study. Although there were many differences in short-term
outcomes in the unmatched cohort, including 30-day mor-
tality (Table 5), for the matched cohort short-term outcomes
were very similar. Thirty-day mortality, postoperativediovascular Surgery c Volume 148, Number 5 1933
TABLE 2. Baseline characteristics for the adjusted propensity-matched and unadjusted registry cohorts, by type of valve
Bioprosthetic Mechanical
P value
Bioprosthetic Mechanical
P valuePropensity-matched cases Registry cases
Cases 361 361 408 571
Patient characteristic
Age 53.9  9.0 53.2  7.8 .298 57.5 6.4 49.7  10.5 .001
Female 30.2 (109) 29.6 (107) .935 26.5 (108) 28.0 (160) .611
Body mass index 29.2 (6.4) 28.9 (6.3) .592 28.1 (5.2) 28.7 (7.2) .213
Hypertension 52.1 (188) 46.8 (169) .180 51.5 (210) 37.5 (214) .001
Hypercholesterolemia 47.1 (170) 50.1 (181) .457 57.1 (233) 36.8 (210) .001
Renal failure 4.7 (17) 3.0 (11) .335 2.7 (11) 3.3 (19) .708
Preoperative creatinine 1.1 (0.8) 1.0 (0.7) .624 1.0 (0.9) 1.1 (0.9) .482
Previous stroke 3.9 (14) 3.0 (11) .685 1.7 (7) 6.2 (35) .001
Congestive heart failure 30.5 (110) 29.4 (106) .807 27.0 (110) 33.5 (191) .035
Endocarditis 6.6 (24) 6.1 (22) .879 4.2 (17) 9.8 (56) .001
New York Heart Association functional class III-IV 30.7 (111) 30.7 (111) 1.000 31.9 (130) 33.6 (192) .638
Ejection fraction (%) 60 (55-65) 60 (55-65) .866 60 (55-65) 55 (50-65) .001
Operative characteristic
Previous cardiac surgery 13.0 (47) 11.4 (41) .570 1.5 (6) 26.4 (151) .001
Previous coronary artery bypass graft 3.0 (11) 3.6 (13) .836 0.7 (3) 5.3 (30) .001
Previous valve 8.3 (30) 8.3 (30) 1.000 0.7 (3) 19.4 (111) .001
Cardiopulmonary bypass time (min) 114 (87-174) 121 (97-183) .167 110 (81-145) 132 (120-247) .001
Ischemic time (min) 80 (61-129) 87 (68-135) .100 81 (59-111) 92 (80-171) .001
Concomitant aortic surgery 23.3 (84) 28.3 (102) .148 20.1 (82) 35.9 (205) .001
Data are presented as mean  standard deviation,% (n), or median (interquartile range).
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Dstroke, and re-exploration for bleeding showed no signifi-
cant differences (Table 5). Length of hospital stay was the
only short-term outcome to show a difference in the
matched cohort, with patients receiving mechanical valves
having a longer hospital stay (P ¼ .02) (Table 5), likely
attributable to the time required to achieve therapeutic anti-
coagulation with warfarin therapy.Late Outcomes—Matched Cohort
For late outcomes therewas no identifiable difference in the
primary outcome of survival out to18 years of follow-up in theTABLE 3. Distribution of valve types implanted
Valve type Registry Match
Bioprosthetic
Total 408 361
Unknown 2 (0.5) 1 (0.3)
St Jude* Medical Biocor Porcine 5 (1.2) 8 (2.2)
Medtronicy Hancock II Porcine 10 (2.5) 35 (9.7)
Sorinz Mitroflow Pericardial 9 (2.2) 3 (0.8)
Carpentier-Edwardsx Perimount Pericardial 380 (93.1) 314 (87.0)
Mechanical
Total 571 361
Unknown 3 (0.5) 1 (0.3)
Sorinz Carbomedics Top Hat Bileaflet 13 (2.3) 19 (5.3)
On-Xjj Bileaflet 5 (0.9) 23 (6.4)
St Jude* Medical Bileaflet 550 (96.3) 318 (88.0)
Data are presented as n (%). *St Jude Medical Inc, St Paul, Minn. yMedtronic, Min-
neapolis, Minn. zSorin, Milan, Italy. xEdwards Lifesciences, Irvine, Calif. jjOn-X
Life Technologies, Austin, Tex.
1934 The Journal of Thoracic and Cardiovascular Surmatched cohort (Figure 2). At 5, 10, 15, and 18 years, life table
estimates for survival in the bioprosthetic group were 89%
2%, 78% 3%, 65%  5%, and 60%  6%, whereas for
the mechanical group they were 88%  2%, 79%  3%,
75%  4%, and 51%  14% (P ¼ .752). There were 65
deaths in the bioprosthetic group of which 16 were cardiac-
related. In themechanical group therewere 61deaths ofwhich
18 were cardiac-related. Still, with the cause of late death
unknown for 43% of the cohort, the true influence of
cardiac-related causes on late survival is most certainly higher
for both groups (Table 6). Freedom from reoperation signifi-
cantly favored mechanical prostheses (P ¼ .002), whereas
freedom frommajor bleeding events significantly favored bio-
prosthetic valves (P ¼ .002) (Figures 3 and 4). There was no
difference in stroke between the 2 groups (P¼ .33) (Figure 5).TABLE 4. Late survival follow-up in years and patient-years
Cohort
Median
(IQR) (y) Range (y) Patient-years
Vita status
follow-up (%)
Total cohort 99*
Bioprosthetic 5 (3-9) 1-18 4998
Mechanical 11 (5-16) 1-18 9850
Matched cohort
Bioprosthetic 7 (4-11) 1-18 2738
Mechanical 6 (3-11) 1-18 2675
Registry cohort
Bioprosthetic 5 (3-8) 1-18 2260
Mechanical 14 (8-17) 1-18 7175
IQR, Interquartile range. *1682 out of 1701.
gery c November 2014
TABLE 5. Short-term outcomes for both the adjusted propensity-matched and unadjusted registry cohorts
Patient characteristic
Type of valve implanted
Bioprosthetic Mechanical
P value
Bioprosthetic Mechanical
P valuePropensity-matched cases Registry cases
Cases 361 361 408 571
Reoperation for bleeding 2.5 (9) 2.5 (9) 1.000 1.5 (6) 3.3 (19) .098
Postoperative stroke 3.3 (12) 2.5 (9) .659 1.5 (6) 4.6 (26) .010
Heart block – PPM 2.5 (9) 4.2 (15) .299 0.7 (3) 5.1 (29) .001
Cardiac arrest 1.7 (6) 1.4 (5) 1.000 1.2 (5) 2.3 (13) .335
Ventilation h 6 (4-11) 6 (4-11) .793 6 (4-10) 7 (4-13) .004
ICU h 39 (24-70) 39 (23-64) .456 38 (24-62) 39 (24-70) .700
Hospital LOS (d) 6 (4-8) 6 (5-8) .020 5 (5-7) 7 (5-9) .001
30-d mortality 1.9 (7) 1.4 (5) .773 1.0 (4) 4.0 (23) .005
Data are presented as% (n) or median (interquartile range). PPM, Permanent pacemaker; ICU, intensive care unit; LOS, length of stay.
McClure et al Acquired Cardiovascular Disease
A
C
DLate Outcomes—Registry Cohort
The late outcomes for the unmatched cohort echoed those
found in the matched cohort. There was no difference in late
survival for the mechanical and bioprosthetic groups in the
unmatched cohort, despite the fact that the mechanical group
in the unmatched cohort had a greater preoperative risk pro-
file than their bioprosthetic counterparts, leading to poorer
short-term in-hospital outcomes. And although there was a
trend toward increased stroke at late follow-up in the me-
chanical group from the unmatched cohort, this did not reach
statistical significance (P¼ .18). Freedom from reoperations
significantly favored mechanical valves and freedom from
major bleeding events favored bioprosthetic valves, just as
it had in the matched cohort comparison (data not shown).
DISCUSSION
Improved outcomes in reoperative aortic valve surgery2,3
along with perceived improvements in the durability of
second-generation bioprostheses4,5 have catalyzed a trendFIGURE 2. Kaplan-Meier survival curve comparing matched
The Journal of Thoracic and Cartoward implanting bioprosthetic valves into younger
patients. With the zealous embracing of percutaneous valve-
in-valve technologyas a treatment alternative forSVD(anovel
yet untested technology), this trend is certain to continue.6,14
Technologies to improve outcomes with mechanical valves
have also materialized over time. Home monitoring systems
to better regulate day-to-day international normalized ratio
levels and mechanical valve prostheses touted to function at
lower levels of anticoagulation have come to market. Still,
the general trend continues to lean toward bioprosthetic valve
implantation over mechanical valve implantation.
In our propensity-matched study comparing 361 patient-
pairs having undergone an AVR with a bileaflet mechanical
valve or a bioprosthetic valve between 1992 and 2011, there
was no difference in the primary outcome of late survival
out to 18 years.
Our results parallel the results of a single randomized
controlled trial comparing bileaflet mechanical valves to
second-generation bioprostheses in middle-aged patientspatient-pairs between bioprosthetic and mechanical valves.
diovascular Surgery c Volume 148, Number 5 1935
TABLE 6. Causes of late death
Cause of death Bioprosthesis group Mechanical group
Cardiac arrest/myocardial
infarction
12 13
Endocarditis 1 0
Stroke 3 5
Cardiac-related 16 18
Pulmonary 1 5
Sepsis 4 6
MSOF 3 2
Renal failure 1 1
Cancer 6 5
Other (noncardiogenic) 2 2
Lost to follow-up 32 22
MSOF, Multisystem organ failure.
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Dwithin the contemporary literature.12 In Stassano and col-
leagues’12 clinical trial of 155 randomized pairs, there
was no difference in survival at a mean 8.8 years followed
out to 13.4 years. On the contrary, Brown and colleagues9
reported a survival advantage for mechanical valves over
bioprostheses in an observational study of 220 case-
matched pairs at 10 years’ follow-up. Stassano and col-
leagues12 and Brown and colleagues9 each assessed
middle-aged patients with an age range of 50 to 70 years,
whereas our study only included patients younger than
age 65 years. Notably, at a mean age of 53.5 years, our
matched cohort was approximately 10 years younger than
the mean age for patients in either of these 2 studies. Other
differences in study design are also important whenFIGURE 3. Kaplan-Meier curve comparing freedom from reoperations be
1936 The Journal of Thoracic and Cardiovascular Surinterpreting the results. We chose to include only those
patients undergoing an isolated AVR. Focused solely on iso-
lated AVRs, we derived a matched group of 361 patient-
pairs with statistically similar postoperative complications,
including 30-day mortality. This suggests evenly matched
patient-pairs capable of producing credible late outcomes
data for insightful interpretation. Stassano and colleagues12
and Brown and colleagues9 included patients having had
either an AVR or an AVR plus coronary artery bypass graft-
ing procedure. Although this is of no consequence for Stas-
sano and colleagues,12 who performed a randomized trial, it
could certainly enable confounding and disproportionate
myocardial ischemic burdens to have materialized within
the presumed evenly matched patients of the analysis by
Brown and colleagues.9 This could have contributed to
the difference in long-term mortality seen within that study
despite efforts to control for this through statistical mea-
sures. The significant difference in 30-day mortality noted
in the matched pairs of the analysis by Brown and col-
leagues9 (with the bioprosthetic group having had a higher
mortality), fuels this speculation. If 2 evenly matched
groups differ only by valve implant, theoretically no differ-
ence in 30-day mortality should arise.
More recently, 2 additional observational studies have
also suggested a survival benefit of mechanical valves
at late follow-up. Badhwar and colleagues10 performed
a propensity-matched analysis comparing second-
generation bioprostheses to the On-X bileaflet mechanical
valve (On-X Life Technologies, Austin, Tex) in a very small
cohort of patients (142 total patients) younger than age 65tween matched patient-pairs with bioprosthetic and mechanical valves.
gery c November 2014
FIGURE 4. Kaplan-Meier curve comparing major bleeding events between matched patient-pairs with bioprosthetic and mechanical valves.
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ingly, the study included all primary isolated left-sided
heart valve replacements (mitral and aortic). Despite pro-
pensity matching, 52% of patients in the mechanical groupFIGURE 5. Kaplan-Meier curve comparing stroke rates between m
The Journal of Thoracic and Carunderwent a mitral valve replacement (48% underwent an
AVR) and were compared with a presumably evenly
matched bioprosthetic group where only 15% underwent
a mitral valve replacement (85% underwent an AVR). Aatched patient-pairs with bioprosthetic and mechanical valves.
diovascular Surgery c Volume 148, Number 5 1937
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valves at 7.5 years’ follow-up. However, to be confident
that patients have been evenly matched when there is a
significantly disproportionate amount of structural left heart
disease in the 2 comparative groups, regardless of the statis-
tical measures, is difficult. The opportunity for confounding
is substantial.
Weber and colleagues11 performed a thorough
propensity-matched analysis to derive 103 patient-pairs
with mean age 50 years but with a very short mean
follow-up of only 2.75 years. Although Weber and col-
leagues11 also had inclusion criteria enabling concomitant
coronary revascularization or additional valve repairs to
have occurred, there was no difference in early mortality
amongst the 2 matched groups. A crude mortality survival
advantage was noted for mechanical valves over biologic
valves in their propensity-matched group. A review of their
article showed that after adjusting for 13 additional poten-
tial confounding variables, this survival advantage was no
longer present (P ¼ .203). Despite this, the authors still
concluded that patients aged younger than 60 years incur
a survival advantage with mechanical valves.
Somewhat surprisingly, in our unmatched cohort wewere
again unable to detect a difference in late survival between
patients receiving mechanical versus bioprosthetic valves.
Although the mechanical group in the unmatched cohort
had a higher risk profile (ie, more redo operations, endocar-
ditis, prior strokes, and poorer ejection fraction), the bio-
prosthetic group was significantly older with a mean age
of 57.5 versus 49.7 years, which may have been the equal-
izing factor to mitigate any survival differences.
The results for secondary outcomes in our study, with ma-
jor bleeding occurring more often with mechanical valves,
reoperations occurring more often with bioprosthetic valves,
and no difference in stroke rates, are similar to previous re-
ports. Second-generation bioprostheses are more durable
than first-generation bioprostheses and anticoagulation is
likely better monitored for mechanical valves in the current
era than prior.However, the overall result relative to 1 another
remains the same: bioprosthetic valves result inmore reoper-
ations and mechanical valves result in more bleeding events.
Our study has several strengths. With 361 evenly
matched pairs, this is the largest cohort comparing bio-
prosthetic and bileaflet mechanical valves in the literature.
By focusing on isolated AVR and excluding concomitant
coronary revascularization and additional valve replace-
ment procedures, key confounders were eliminated from
the analysis. Our propensity model was robust and our
follow-up for the primary outcome was 99% complete
over an extended period.
Limitations
Ours was a retrospective, single-center observational
study. All such studies are at risk for an underestimation1938 The Journal of Thoracic and Cardiovascular Surof events. Despite a systematic and exhaustive chart review
with multiple layers of cross-referencing the database to
ensure accuracy in addition to input from patient question-
naires, an underestimation of late events (eg, reoperations,
major bleeding, and strokes) is still plausible. Specific to
the questionnaire responses, recall bias, where patients sim-
ply forget prior adverse events (having happened several
years prior), will result in some degree of underestimation.
Additionally, it is possible that those who did not respond to
our questionnaire (for whom secondary outcome data was
acquired solely from the EMR), did in fact have worse sec-
ondary outcomes than responders and thus the overall rep-
resentation is underestimated. Our responder bias analysis
suggests otherwise, because no clear differences were iden-
tified; this supports that their information is missing at
random but this cannot be known with absolute certainty.
Assuming such underestimation is evenly distributed across
the cohort, the overall effect of such underestimation on
group comparisons between patients with a bioprosthesis
and a mechanical prosthesis that have been evenly matched
in a pairwise fashion should be rather noncontributory.13
Despite our efforts to create a clinically matched subset
of comparable patients using a comprehensive stepwise lo-
gistic regression propensity-score analysis, there is always
the potential for confounding due to unforeseen and unmea-
surable covariates.CONCLUSIONS
In nonelderly (ie, younger than age 65 years) patient pop-
ulations, despite an increase in bleeding events with me-
chanical valves and an increased rate of reoperation with
stented bioprosthetic valves, choice of valve prosthesis
does not appear to affect late survival.References
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